POLA1 and infection: Pola-BR resulted in a significantly higher CRR (40.0% vs. 17.5%), longer PFS (9.5 vs. 3.7 months; p < 0.001), and longer OS (12.4 vs. 4.7 months; p = 0.002) compared with BR alone; however, Pola-BR patients had a higher rate of hematological toxicity but similar grade 3–4 infections.